Zoetis Inc. (ZTS) SEC Filings
Filing links are provided when reliable SEC filing data is available.
Recent Filings
| Form | Filing Date | Accepted | Document |
|---|---|---|---|
| SD | May 28, 2026 | May 28, 2026 | View filing |
| 4 | May 26, 2026 | May 26, 2026 | View filing |
| 8-K | May 22, 2026 | May 21, 2026 | View filing |
| 4 | May 21, 2026 | May 21, 2026 | View filing |
| 8-K | May 20, 2026 | May 20, 2026 | View filing |
| 4 | May 13, 2026 | May 13, 2026 | View filing |
| 4 | May 13, 2026 | May 13, 2026 | View filing |
| 4 | May 12, 2026 | May 12, 2026 | View filing |
| 10-Q | May 7, 2026 | May 7, 2026 | View filing |
| 8-K | May 7, 2026 | May 7, 2026 | View filing |
| 4 | May 1, 2026 | May 1, 2026 | View filing |
| SC 13G | Apr 30, 2026 | Apr 30, 2026 | View filing |
| SC 13G | Apr 29, 2026 | Apr 29, 2026 | View filing |
| 4 | Apr 13, 2026 | Apr 13, 2026 | View filing |
| 4 | Apr 13, 2026 | Apr 13, 2026 | View filing |
| 4 | Apr 13, 2026 | Apr 13, 2026 | View filing |
| 4 | Apr 13, 2026 | Apr 13, 2026 | View filing |
| 4 | Apr 13, 2026 | Apr 13, 2026 | View filing |
| 4 | Apr 13, 2026 | Apr 13, 2026 | View filing |
| 4 | Apr 13, 2026 | Apr 13, 2026 | View filing |
| 4 | Apr 13, 2026 | Apr 13, 2026 | View filing |
| ARS | Apr 8, 2026 | Apr 8, 2026 | View filing |
| DEFA14A | Apr 8, 2026 | Apr 8, 2026 | View filing |
| DEF 14A | Apr 8, 2026 | Apr 8, 2026 | View filing |
| 4 | Apr 1, 2026 | Apr 1, 2026 | View filing |
| 4 | Mar 31, 2026 | Mar 31, 2026 | View filing |
| 4 | Mar 31, 2026 | Mar 31, 2026 | View filing |
| 4 | Mar 31, 2026 | Mar 31, 2026 | View filing |
| 4 | Mar 31, 2026 | Mar 31, 2026 | View filing |
| 4 | Mar 31, 2026 | Mar 31, 2026 | View filing |
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck